Brothers Rakesh Popat, PhD, multiple myeloma expert, and Sanjay Popat, PhD, thoracic oncologist, join the show for a special discourse on surrogate endpoints and patient benefit. The conversation fluctuates between the “assumption” that surrogate endpoints translate to better survival; breakdowns of the utility and association with overall survival of PFS, ORR, and MRD in the latest literature; reimbursement intricacies and issues surrounding surrogate endpoint criteria; and the need for stronger confirmatory trials after accelerated approvals, along with plenty more important points for consideration.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
